Needle Sticks, Sharps and Bloodborne Pathogen Exposures

 


Sharps

Medication Schedule

RECOMMENDATIONS FOR NON-PREGNANT PERSONS:

Dolutegravir 50 mg tablet (Tivicay) - One tablet by mouth with or without food once daily for 4 weeks.

AND

Emtricitabine/Tenofovir 200mg/300mg tablet (Truvada) - One tablet by mouth with or without food once daily for 4 weeks.

RECOMMENDATIONS FOR PERSONS KNOWN TO BE PREGNANT:

Emtricitabine/Tenofovir 200mg/300mg tablet (Truvada) - One tablet by mouth with or without food once daily for 4 weeks

AND

Raltegravir 400 mg tab/dose – Twice daily for 4 weeks
Side effects associated with Dolutegravir (Tivicay) and Raltegravir (Isentress) include nausea, diarrhea, headache, dizziness, abnormal dreams and difficulty sleeping. Rarely, these medications may cause jaundice with dark urine and yellowing of the skin or eyes.

Side effects associated with emtricitabine/tenofovir (Truvada) include nausea, vomiting, diarrhea, abdominal pain, dizziness, gas, loss of appetite, headache, rash, skin discoloration, joint pain and muscle pain. Rarely, this medication may cause jaundice with dark urine and yellowing of the skin or eyes.


The medication regimen above may change based on the latest recommendations from the Centers for Disease Control. For more information, please refer to the UTMB Policy for BBP Exposures or consult UTMB Healthcare Epidemiology.